Literature DB >> 2854956

Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus.

D F Smee1, H A Alaghamandan, G D Kini, R K Robins.   

Abstract

Ribavirin 5'-sulfamate, a nucleotide analog, inhibited Semliki Forest virus cytopathology by 50% at 10 microM, whereas ribavirin was inactive at less than or equal to 1 mM. Actinomycin D did not reverse (antagonize) the effect of ribavirin 5'-sulfamate against the virus. The compound inhibited amino acid incorporation into macromolecules of uninfected cells but had no appreciable effect on uridine incorporation. Infected cells treated with actinomycin D and nucleotide analog were inhibited in amino acid and uridine incorporation. The compound blocked the formation of the viral RNA polymerase protein in cells, which could account for the inhibited synthesis of new viral RNA. By electrophoresis, inhibition of the synthesis of viral proteins was more pronounced than the inhibition of cellular polypeptides. The analog inhibited the translation of mRNA to protein. Most animals treated intraperitoneally for 7 days with ribavirin 5'-sulfamate at 20 and 40 mg/kg/day starting 2 h before intraperitoneal Semliki Forest virus inoculation survived the otherwise lethal infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854956     DOI: 10.1016/0166-3542(88)90044-7

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  2 in total

Review 1.  A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses.

Authors:  Kuan-Chieh Ching; Lisa F P Ng; Christina L L Chai
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

Review 2.  Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy.

Authors:  Simon-Djamel Thiberville; Nanikaly Moyen; Laurence Dupuis-Maguiraga; Antoine Nougairede; Ernest A Gould; Pierre Roques; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2013-06-28       Impact factor: 5.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.